Registered title, quoted from ClinicalTrials.gov
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT03193567, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
pathologically confirmed non-small cell lung cancer.
Inclusion criterion 3
Karnofsky performance status 0-1.
Inclusion criterion 5
Pregnant and lactating women.
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03193567, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female patients' age from 18 years to 70 years.
- Patients who have a life expectancy of at least 3 months.
- pathologically confirmed non-small cell lung cancer.
- failed in previous standard chemotherapy and targeted therapy.
- Karnofsky performance status 0-1.
- adequate organ functions.
Exclusion Criteria:
- Pregnant and lactating women.
- Patients with T cell lymphoma, syphilis, AIDS or combination
- Patients with highly allergic or have a history of severe allergies
- Patients with severe hepatic or renal dysfunction
- Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
- Patients with severe infection not controlled or High fever
- Patients with organ transplantation or waiting for organ transplantation.
- Patients with brain metastasis
- Patients with severe coagulopathy (e.g. hemophilia)
- Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.
Quoted from ClinicalTrials.gov, NCT03193567, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT03193567, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.